Journal article
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
N Frey, JH Jang, J Szer, Á Illés, HJ Kim, R Ram, BH Chong, JM Rowe, E Borisenkova, J Liesveld, ES Winer, A Cherfi, V Aslanis, F Ghaznawi, S Strickland
Lancet Haematology | ELSEVIER SCI LTD | Published : 2019
Abstract
Background: Patients with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a similar mechanism to endogenous thrombopoietin. This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia. Methods: In this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA). Patients with acute myeloid leukaemia of any sub..
View full abstractGrants
Funding Acknowledgements
This study was funded by Novartis Pharma AG. We thank all the patients and co-investigators for their participation and contribution to this study. We thank Rebecca Helson of Mudskipper Business Ltd for medical editorial assistance. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.